|Download document||Draft guideline on core summary of product characteristics for human fibrinogen products|
|Reference number||EMA/CHMP/BPWP/691754/2013 Rev. 1|
|Status||draft: consultation open|
|Consultation start date||04/03/2014|
|Consultation end date||04/06/2014|
|Email address for firstname.lastname@example.org|
This guideline describes the information to be included in the summary of product characteristics for human fibrinogen, which is indicated for the treatment and prophylaxis of bleeding in patients with congenital hypo-, dys- or afibrinogenaemia with bleeding tendency and as a complementary therapy to management of uncontrolled severe haemorrhage in acquired hypofibrinogenaemia.